

Cite as: *Can Urol Assoc J* 2021;15(5):E304. <http://dx.doi.org/10.5489/cuaj.7321>

## Erratum 1 – Olaparib indication in CRPC guideline

In the guideline entitled, “2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC),” published in the February 2021 issue of *CUAJ* (Citation: Saad F, Aprikian A, Finelli A, et al. *Can Urol Assoc J* 2021;15(2):E81-9. <http://dx.doi.org/10.5489/cuaj.7074>), the correct indication for olaparib should have read as follows: “The Health Canada approval of olaparib is for patients with deleterious or suspected deleterious germline or somatic BRCA1/2 or ATM mutations who have progressed following prior treatment with an NHT (i.e., abiraterone, enzalutamide, apalutamide, darolutamide).” Furthermore, Fig. 1 should have listed olaparib in the mCRPC first-line treatment box with an asterisk indicating, “For patients with HRR mutation and having progressed on an NHT.” *CUAJ* regrets the oversight and apologizes for any inconvenience. Visit <https://cuaj.ca/index.php/journal/article/view/7074/4792> for a corrected version of the paper.

## Erratum 2 – Abstract added to testis cancer review

In the special feature entitled, “Controversies in the management of clinical stage 1 testis cancer,” (Citation: Nason GJ, Chung P, Warde P, et al. *Can Urol Assoc J* 2020;14(11):E537-42. <http://dx.doi.org/10.5489/cuaj.6722>), the abstract was left out of the final publication and has been added back. Visit <https://cuaj.ca/index.php/journal/article/view/6722/4666> for an updated version of the paper.